Atara Biotherapeutics Inc. (ATRA) CFO John Mcgrath Sells 5,000 Shares
Atara Biotherapeutics Inc. (NASDAQ:ATRA) CFO John Mcgrath sold 5,000 shares of Atara Biotherapeutics stock in a transaction on Wednesday, October 12th. The stock was sold at an average price of $17.47, for a total value of $87,350.00. Following the transaction, the chief financial officer now directly owns 96,823 shares of the company’s stock, valued at $1,691,497.81. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Atara Biotherapeutics Inc. (NASDAQ:ATRA) opened at 15.75 on Friday. The firm’s 50-day moving average is $19.73 and its 200 day moving average is $20.25. Atara Biotherapeutics Inc. has a 52-week low of $13.31 and a 52-week high of $40.80. The firm’s market capitalization is $453.77 million.
Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings data on Monday, August 8th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.61) by $0.05. Equities analysts anticipate that Atara Biotherapeutics Inc. will post ($2.85) EPS for the current year.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/14/atara-biotherapeutics-inc-atra-cfo-john-mcgrath-sells-5000-shares.html
Several equities analysts recently issued reports on ATRA shares. Zacks Investment Research cut Atara Biotherapeutics from a “hold” rating to a “sell” rating in a report on Thursday, September 22nd. Goldman Sachs Group Inc. downgraded Atara Biotherapeutics from a “neutral” rating to a “sell” rating and dropped their price target for the stock from $23.00 to $16.00 in a research report on Thursday, September 15th. Citigroup Inc. raised their price target on Atara Biotherapeutics from $8.00 to $10.00 and gave the stock a “sell” rating in a research report on Friday, August 19th. Jefferies Group reissued a “buy” rating and set a $25.00 price target on shares of Atara Biotherapeutics in a research report on Sunday, July 10th. Finally, JMP Securities reissued a “buy” rating on shares of Atara Biotherapeutics in a research report on Saturday, July 9th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $26.14.
A number of institutional investors have recently made changes to their positions in the stock. FMR LLC boosted its position in shares of Atara Biotherapeutics by 29.9% in the second quarter. FMR LLC now owns 3,125,407 shares of the company’s stock worth $70,353,000 after buying an additional 720,313 shares during the last quarter. Redmile Group LLC boosted its position in shares of Atara Biotherapeutics by 5.9% in the second quarter. Redmile Group LLC now owns 2,408,970 shares of the company’s stock worth $54,226,000 after buying an additional 133,205 shares during the last quarter. Eagle Asset Management Inc. boosted its position in shares of Atara Biotherapeutics by 0.8% in the third quarter. Eagle Asset Management Inc. now owns 980,673 shares of the company’s stock worth $20,976,000 after buying an additional 8,081 shares during the last quarter. BlackRock Fund Advisors boosted its position in shares of Atara Biotherapeutics by 18.6% in the second quarter. BlackRock Fund Advisors now owns 913,922 shares of the company’s stock worth $20,572,000 after buying an additional 143,242 shares during the last quarter. Finally, Bridger Management LLC acquired a new position in shares of Atara Biotherapeutics during the first quarter worth about $14,072,000. 75.50% of the stock is currently owned by hedge funds and other institutional investors.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.
Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.